Ginkgo Bioworks Holdings, Inc.
DNANYSEHealthcare● Active
$8.22
+$0.00(+0.00%)
Market Cap$536967357
P/E Ratio—
52W High$17.58
52W Low$5.37
Ginkgo Bioworks Holdings, Inc. (DNA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DNA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.28
Est. -$1.21 · -5.7%
Revenue
$0.02B
Est. $0.04B · -54.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
DNA reports quarterly as a NYSE-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$1.05 | — | — | — | $0.03B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$1.21 | -$1.28 | -5.7% | $0.02B | $0.04B | -54.6% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$1.80 | -$1.42 | +21.1% | $0.03B | $0.04B | -11.0% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$1.24 | -$1.45 | -16.9% | $0.04B | $0.04B | +3.4% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$1.44 | -$1.10 | +23.6% | $0.05B | $0.04B | +27.4% |
| ▼ Q2 FY2025 | May 6, 2025 | -$1.23 | -$1.58 | -28.5% | $0.05B | $0.04B | +16.2% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -$1.45 | -$1.82 | -25.5% | $0.04B | $0.04B | +13.3% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$2.40 | -$1.08 | +55.0% | $0.09B | $0.04B | +100.4% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$1.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$1.28
EPS Est.
-$1.21
EPS Surpr.
-5.7%
Revenue
$0.02B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$1.42
EPS Est.
-$1.80
EPS Surpr.
+21.1%
Revenue
$0.03B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$1.45
EPS Est.
-$1.24
EPS Surpr.
-16.9%
Revenue
$0.04B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$1.10
EPS Est.
-$1.44
EPS Surpr.
+23.6%
Revenue
$0.05B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$1.58
EPS Est.
-$1.23
EPS Surpr.
-28.5%
Revenue
$0.05B
Q1 FY2025
Feb 25, 2025Miss
EPS Actual
-$1.82
EPS Est.
-$1.45
EPS Surpr.
-25.5%
Revenue
$0.04B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$1.08
EPS Est.
-$2.40
EPS Surpr.
+55.0%
Revenue
$0.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.04 | $-1.00 | $-0.96 | 1 |
| Q3 FY2027 | $-1.14 | $-1.09 | $-1.04 | 1 |
| Q2 FY2027 | $-1.24 | $-1.19 | $-1.14 | 1 |
| Q1 FY2027 | $-1.47 | $-1.41 | $-1.35 | 1 |
| Q4 FY2026 | $-1.30 | $-1.25 | $-1.20 | 1 |
| Q3 FY2026 | $-1.26 | $-1.21 | $-1.16 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -5.7% | $10.08 | $10.32 | +2.38% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +21.1% | $9.38 | $9.71 | +3.52% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -16.9% | $11.59 | $11.30 | -2.50% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +23.6% | $13.96 | $13.46 | -3.58% |
| ▼ Q2 FY2025 | May 6, 2025 | -28.5% | $6.92 | $6.45 | -6.79% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -25.5% | $10.46 | $10.29 | -1.63% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +55.0% | $8.76 | $8.39 | -4.22% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +0.0% | $10.98 | $11.43 | +4.10% |
Q2 FY2026+2.38%
Report Date
May 7, 2026
EPS Beat/Miss
-5.7%
Price Before
$10.08
Price After
$10.32
Q1 FY2026+3.52%
Report Date
Feb 26, 2026
EPS Beat/Miss
+21.1%
Price Before
$9.38
Price After
$9.71
Q4 FY2025-2.50%
Report Date
Nov 6, 2025
EPS Beat/Miss
-16.9%
Price Before
$11.59
Price After
$11.30
Q3 FY2025-3.58%
Report Date
Aug 7, 2025
EPS Beat/Miss
+23.6%
Price Before
$13.96
Price After
$13.46
Q2 FY2025-6.79%
Report Date
May 6, 2025
EPS Beat/Miss
-28.5%
Price Before
$6.92
Price After
$6.45
Q1 FY2025-1.63%
Report Date
Feb 25, 2025
EPS Beat/Miss
-25.5%
Price Before
$10.46
Price After
$10.29
Q4 FY2024-4.22%
Report Date
Nov 12, 2024
EPS Beat/Miss
+55.0%
Price Before
$8.76
Price After
$8.39
Q3 FY2024+4.10%
Report Date
Aug 8, 2024
EPS Beat/Miss
+0.0%
Price Before
$10.98
Price After
$11.43
Avg Beat Reaction-0.04%
Avg Miss Reaction-2.13%
Beat Rate4 / 8 quarters
Largest Move-6.79% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DNA ends December
Ginkgo Bioworks Holdings, Inc. (DNA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.28 — missing the analyst consensus of $-1.21 by -5.7%. The next DNA earnings date is expected around September 1, 2026.
Each quarter, investors track DNA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DNA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DNA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DNA earnings · 5 questionsGinkgo Bioworks Holdings, Inc.'s next earnings report is expected around September 1, 2026. DNA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DNA historically reports after market close (AMC).
DNA earnings datewhen is DNA earningsDNA next earnings datewhen does DNA report earningsDNA earnings calendar
▸ Source: FMP · Ginkgo Bioworks Holdings, Inc. SEC filings · US GAAP · Ginkgo Bioworks Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026